Article
SR One breaks off from GlaxoSmithKline, banks $500M fund
Rating:
0.0
Views:
55
Likes:
1
Library:
1
SR One has backed biotech companies for decades as GlaxoSmithKline's venture arm. Now, the firm is striking out on its own, having spun out from the British conglomerate and raised a whopping $500 million fund. The fund, SR One's first, will back “elite” biotechs on both sides of the Atlantic, working on new medicines to address treatment gaps.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value